Skip to main content
Atrás
COLL logo

Collegium Pharmaceutical, Inc.

Calidad de datos: 100%
Sobreventa
COLL
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$33.25
▲ $0.02 (0.06%)
Cap. Mercado: 1.06B
Rango del Día
$33.20 $33.76
Rango de 52 Semanas
$23.23 $50.79
Volumen
634,834
Promedio 50D / 200D
$43.32 / $38.94
Cierre Anterior
$33.23

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E 16.8 0.2
P/B 3.5 3.0
ROE % 23.7 3.6
Net Margin % 8.1 3.8
Rev Growth 5Y % 29.6 9.9
D/E 3.1 0.2

Precio Objetivo de Analistas

Hold
$58.00 +74.4%
Low: $56.00 High: $60.00
P/E Futuro
4.10
EPS Futuro
$8.11
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
809.53M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $9.39
$8.49 – $10.40
 767.90M 1
FY2029 $8.88
$8.03 – $9.84
 741.80M 1
FY2028 $7.24
$6.55 – $8.02
 662.95M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 $2.14 $2.04 -4.7%
2025-11-06 $1.86 $2.25 +21.0%
2025-08-07 $1.62 $1.68 +3.7%
2025-05-08 $1.43 $1.49 +4.2%
2025-02-27 $1.54 $1.77 +14.9%
2024-11-07 $1.59 $1.61 +1.3%
2024-08-08 $1.49 $1.62 +8.7%
2024-05-09 $1.47 $1.45 -1.4%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 29.58% annually over 5 years — strong growth
ROE of 23.70% indicates high profitability
Debt/Equity of 3.12 — high leverage
Generating 327.58M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 5.96%
Cash machine — converts 521.05% of earnings into free cash flow

Crecimiento

Revenue Growth (5Y)
29.58%
Revenue (1Y)23.62%
Earnings (1Y)-9.13%
FCF Growth (3Y)9.28%

Calidad

Return on Equity
23.70%
ROIC11.30%
Net Margin8.05%
Op. Margin23.97%

Seguridad

Debt / Equity
3.12
Current Ratio1.57
Interest Coverage2.27

Valoración

P/E Ratio
16.79
Forward P/E4.10
P/B Ratio3.50
EV/EBITDA9.33
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 23.62% Revenue Growth (3Y) 17.36%
Earnings Growth (1Y) -9.13% Earnings Growth (3Y) 14.26%
Revenue Growth (5Y) 29.58% Earnings Growth (5Y) -3.17%
Profitability
Revenue (TTM) 780.57M Net Income (TTM) 62.87M
ROE 23.70% ROA 3.79%
Gross Margin 59.35% Operating Margin 23.97%
Net Margin 8.05% Free Cash Flow (TTM) 327.58M
ROIC 11.30% FCF Growth (3Y) 9.28%
Safety
Debt / Equity 3.12 Current Ratio 1.57
Interest Coverage 2.27
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 16.79 Forward P/E 4.10
P/B Ratio 3.50 P/S Ratio 1.35
PEG Ratio -3.12 Forward PEG N/A
EV/EBITDA 9.33 Fwd EV/EBITDA 4.72
Forward P/S 1.30 Fwd Earnings Yield 24.39%
FCF Yield 31.03%
Market Cap 1.06B Enterprise Value 1.75B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 780.57M 631.45M 566.77M 463.93M 276.87M
Net Income 62.87M 69.19M 48.16M -25.00M 71.52M
EPS (Diluted) 1.73 1.86 1.29 -0.74 1.86
Gross Profit 463.26M 377.34M 326.17M 209.49M 150.62M
Operating Income 187.08M 169.90M 166.96M 33.32M 17.63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.66B 1.66B 1.14B 1.17B 692.08M
Total Liabilities 1.36B 1.43B 947.88M 979.29M 489.15M
Shareholders' Equity 301.68M 228.84M 195.43M 194.84M 202.93M
Total Debt 940.56M 859.30M 674.28M 709.18M 258.75M
Cash & Equivalents 251.10M 70.57M 238.95M 173.69M 186.43M
Current Assets 691.41M 482.26M 537.60M 419.99M 315.54M
Current Liabilities 440.03M 509.51M 457.92M 433.73M 279.57M